Serenza Therapeutics

Private

Last Round

Series A

May 10, 2026

Momentum Score

25 /100

Company Overview

Serenza Therapeutics is a biopharmaceutical company spun-out from Nxera Pharma to advance a preclinical GPCR-targeted program.

Historical view of private secondary pricing and transaction trends.

Proprietary index based on bid/ask volume and sentiment.

Track how buyer interest and sentiment changes over time.

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

Access detailed peer comparisons, multiples, and valuation benchmarks.

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	May 10, 2026

Notable investors and investment history

Investor	Rounds
SV Health Investors	Series A

Structured signals derived from secondary market and firmographic data.

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

SEC and related filings with document metadata.

Common questions about Serenza Therapeutics's valuation, stock price, and market status.

HeadquartersLondon

Employee Range30

Year Founded2026

Last FundingMay 10, 2026

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.